The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia
| Autor: | Shane E. Brogan, Steven D Larsen, Andrew P. Dalley, Willem Collier, Jill E Sindt |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Antineoplastic Agents Neutropenia Young Adult 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine 030202 anesthesiology Internal medicine medicine Humans Pain Management Surgical Wound Infection Infusions Spinal Aged Aged 80 and over Drug Implants Chemotherapy Leukopenia business.industry Cancer Pain Perioperative Middle Aged medicine.disease Radiation therapy Anesthesiology and Pain Medicine Absolute neutrophil count Female Implant medicine.symptom Cancer pain business 030217 neurology & neurosurgery |
| Zdroj: | Anesthesia & Analgesia. 131:280-287 |
| ISSN: | 0003-2999 |
| DOI: | 10.1213/ane.0000000000004639 |
| Popis: | BACKGROUND The efficacy of intrathecal drug delivery (IDD) for cancer-related pain is well established. Cancer therapies are often associated with immunosuppression and increased risk of infection, and the rate of infection after intrathecal drug delivery system (IDDS) implant in cancer patients has been reported as 2.4%-6.3%. Our objective is to report on the rate of surgical site infections (SSI) in patients implanted with IDDS for cancer-related pain and to provide a data-driven discussion on the relationship between antineoplastic treatment, leukopenia, and other clinical or demographic characteristics and SSI. METHODS Following local institutional review board approval, we conducted a retrospective chart review of IDDS implants from May 2014 through December 2018. Data collected included demographic data, health status, prophylactic antibiotic administration, surgery duration, presence of leukopenia (white blood cell [WBC] count of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|